Ongoing Disclosure Notices – Employee Share Purchase Plan

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
11 March 2025
Date of last disclosure:
23 September 2024
Director or senior manager giving disclosure
Full name(s):
Andrew Robert Donald Somervell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
110,322 Ordinary Shares
Number held in class after acquisition or disposal:
110,322 Ordinary Shares
Current registered holder(s):
Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:
Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
10 March 2025
Nature of transaction:
Shares transferred from trustee to individual
following completion of restrictive period for 2022
Employee Share Purchase Plan.
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
NZD $491.95
Number of financial products to which the transaction related:
35 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 144,531 Options
b) 49,717 Performance Share Rights
Current registered holder(s):
Andrew Robert Donald Somervell
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
11 March 2025
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
11 March 2025
Date of last disclosure:
24 September 2024
Director or senior manager giving disclosure
Full name(s):
Andrew Grant Niccol
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Operating Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
3,500 Ordinary Shares
Number held in class after acquisition or disposal:
3,500 Ordinary Shares
Current registered holder(s):
Andrew Grant Niccol
Registered holder(s) once transfers are registered:
Andrew Grant Niccol
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
10 March 2025
Nature of transaction:
Shares transferred from trustee to individual
following completion of restrictive period for 2022
Employee Share Purchase Plan.
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
NZD $491.95
Number of financial products to which the transaction related:
35 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 34,587 Options
b) 12,011 Performance Share Rights
Current registered holder(s):Andrew Grant Niccol
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
11 March 2025
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
11 March 2025
Date of last disclosure:
17 September 2024
Director or senior manager giving disclosure
Full name(s):
Lewis George Gradon
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
574,165 Ordinary Shares
Number held in class after acquisition or disposal:
574,165 Ordinary Shares
Current registered holder(s):
Lewis George Gradon; Gradon Family Trust
Registered holder(s) once transfers are registered:
Lewis George Gradon; Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One

Details of transactions requiring disclosure-
Date of transaction:
10 March 2025
Nature of transaction:
Shares transferred from trustee to individual
following completion of restrictive period for 2022
Employee Share Purchase Plan.
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
NZD $1,495.92
Number of financial products to which the transaction related:
71 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of relevant interest:
a) Beneficial Interest
b) Beneficial Interest
For that relevant interest,-
Number held in class:
a) 470,992 Options
b) 159,726 Performance Share Rights
Current registered holder(s):
a) Lewis George Gradon
b) Lewis George Gradon
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
11 March 2025
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
11 March 2025
Date of last disclosure:
17 September 2024
Director or senior manager giving disclosure
Full name(s):
Lyndal Jane York
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
26,525 Ordinary Shares
Number held in class after acquisition or disposal:
26,525 Ordinary Shares
Current registered holder(s):Lyndal Jane York and Alexander Eric York
Registered holder(s) once transfers are registered:Lyndal Jane York and Alexander Eric York
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:
10 March 2025
Nature of transaction:
Shares transferred from trustee to individual
following completion of restrictive period for 2022
Employee Share Purchase Plan.
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
NZD $1,495.92
Number of financial products to which the transaction related:
71 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of relevant interest:
a) Beneficial Interest
b) Beneficial Interest
For that relevant interest,-
Number held in class:
a) 203,534 Options
b) 74,560 Performance Share Rights
Current registered holder(s):
a) Lyndal Jane York
b) Lyndal Jane York
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
11 March 2025
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary